000 01345 a2200349 4500
005 20250518054122.0
264 0 _c20210106
008 202101s 0 0 eng d
022 _a1537-6591
024 7 _a10.1093/cid/ciz784
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aMiyahara, Sachiko
245 0 0 _aApplying a Risk-benefit Analysis to Outcomes in Tuberculosis Clinical Trials.
_h[electronic resource]
260 _bClinical infectious diseases : an official publication of the Infectious Diseases Society of America
_c02 2020
300 _a698-703 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, N.I.H., Extramural
650 0 4 _aAntitubercular Agents
_xtherapeutic use
650 0 4 _aClinical Trials as Topic
650 0 4 _aHumans
650 0 4 _aIsoniazid
650 0 4 _aRisk Assessment
650 0 4 _aTuberculosis
_xdrug therapy
700 1 _aRamchandani, Ritesh
700 1 _aKim, Soyeon
700 1 _aEvans, Scott R
700 1 _aGupta, Amita
700 1 _aSwindells, Susan
700 1 _aChaisson, Richard E
700 1 _aMontepiedra, Grace
773 0 _tClinical infectious diseases : an official publication of the Infectious Diseases Society of America
_gvol. 70
_gno. 4
_gp. 698-703
856 4 0 _uhttps://doi.org/10.1093/cid/ciz784
_zAvailable from publisher's website
999 _c30006990
_d30006990